- In January 2025, The National Health Service (NHS) in England began offering liquid biopsies to women with mutated breast cancer. This ultra-sensitive blood test detects tumor DNA, enabling personalized treatment with targeted therapies such as elacestrant
- In June 2024, Researchers unveiled a predictive blood test capable of detecting breast cancer recurrence up to three years before tumors are visible on scans. Utilizing whole genome sequencing, the test identifies specific mutations, enhancing early intervention strategies
- In March 2024, Guardant Health announced the launch of its new liquid biopsy test, Guardant360 CDx, which is now FDA-approved as a companion diagnostic for multiple cancer types. This blood-based test helps identify actionable mutations in cancer patients, providing physicians with insights into the most effective targeted therapies for individual patients
- In February 2024 Twist Bioscience Corporation introduced a cfDNA Library Preparation Kit to facilitate liquid biopsy research. This kit streamlines sample preparation for next-generation sequencing, enhancing the efficiency of liquid biopsy studies
